Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

706 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Standard dose raltegravir or efavirenz-based antiretroviral treatment for patients co-infected with HIV and tuberculosis (ANRS 12 300 Reflate TB 2): an open-label, non-inferiority, randomised, phase 3 trial.
De Castro N, Marcy O, Chazallon C, Messou E, Eholié S, N'takpe JB, Bhatt N, Khosa C, Timana Massango I, Laureillard D, Chau GD, Domergue A, Veloso V, Escada R, Wagner Cardoso S, Delaugerre C, Anglaret X, Molina JM, Grinsztejn B; ANRS 12300 Reflate TB2 study group. De Castro N, et al. Among authors: bhatt n, n takpe jb. Lancet Infect Dis. 2021 Jun;21(6):813-822. doi: 10.1016/S1473-3099(20)30869-0. Epub 2021 Mar 2. Lancet Infect Dis. 2021. PMID: 33667406 Clinical Trial.
Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial.
Bonnet M, Bhatt N, Baudin E, Silva C, Michon C, Taburet AM, Ciaffi L, Sobry A, Bastos R, Nunes E, Rouzioux C, Jani I, Calmy A; CARINEMO study group. Bonnet M, et al. Among authors: bhatt n. Lancet Infect Dis. 2013 Apr;13(4):303-12. doi: 10.1016/S1473-3099(13)70007-0. Epub 2013 Feb 20. Lancet Infect Dis. 2013. PMID: 23433590 Free article. Clinical Trial.
Pharmacokinetics of rifampin and isoniazid in tuberculosis-HIV-coinfected patients receiving nevirapine- or efavirenz-based antiretroviral treatment.
Bhatt NB, Barau C, Amin A, Baudin E, Meggi B, Silva C, Furlan V, Grinsztejn B, Barrail-Tran A, Bonnet M, Taburet AM; ANRS 12146-CARINEMO Study Group. Bhatt NB, et al. Antimicrob Agents Chemother. 2014 Jun;58(6):3182-90. doi: 10.1128/AAC.02379-13. Epub 2014 Mar 24. Antimicrob Agents Chemother. 2014. PMID: 24663014 Free PMC article. Clinical Trial.
First Report of Prevalence of HTLV-1 Among HIV-1/2-Infected Children in Mozambique.
Manhiça I, Bhatt N, Ismael N, Nhavene E, Grinsztejn B, Veloso V, Maueia C, Augusto O, Jani I, Gudo ES. Manhiça I, et al. Among authors: bhatt n. J Acquir Immune Defic Syndr. 2017 Feb 1;74(2):e54-e56. doi: 10.1097/QAI.0000000000001194. J Acquir Immune Defic Syndr. 2017. PMID: 27753683 No abstract available.
Compromise of Second-Line Antiretroviral Therapy Due to High Rates of Human Immunodeficiency Virus Drug Resistance in Mozambican Treatment-Experienced Children With Virologic Failure.
Vaz P, Buck WC, Bhatt N, Bila D, Auld A, Houston J, Cossa L, Alfredo C, Jobarteh K, Sabatier J, Macassa E, Sousa A, DeVos J, Jani I, Yang C. Vaz P, et al. Among authors: bhatt n. J Pediatric Infect Dis Soc. 2020 Feb 28;9(1):6-13. doi: 10.1093/jpids/piy102. J Pediatric Infect Dis Soc. 2020. PMID: 30364958
706 results